You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
|
---|---|
Published in |
Lancet Oncology, March 2018
|
DOI | 10.1016/s1470-2045(18)30142-6 |
Pubmed ID | |
Authors |
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer, Vanna Chiarion-Sileni, Caroline Dutriaux, Jan Willem B de Groot, Naoya Yamazaki, Carmen Loquai, Laure A Moutouh-de Parseval, Michael D Pickard, Victor Sandor, Caroline Robert, Keith T Flaherty |
X Demographics
The data shown below were collected from the profiles of 31 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
France | 3 | 10% |
United States | 3 | 10% |
Romania | 1 | 3% |
Portugal | 1 | 3% |
India | 1 | 3% |
Brazil | 1 | 3% |
Mexico | 1 | 3% |
Unknown | 20 | 65% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 21 | 68% |
Practitioners (doctors, other healthcare professionals) | 7 | 23% |
Scientists | 3 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 476 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 476 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 62 | 13% |
Researcher | 51 | 11% |
Other | 46 | 10% |
Student > Bachelor | 41 | 9% |
Student > Master | 36 | 8% |
Other | 76 | 16% |
Unknown | 164 | 34% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 142 | 30% |
Biochemistry, Genetics and Molecular Biology | 59 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 33 | 7% |
Agricultural and Biological Sciences | 17 | 4% |
Chemistry | 9 | 2% |
Other | 32 | 7% |
Unknown | 184 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 538. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 November 2023.
All research outputs
#46,446
of 25,837,817 outputs
Outputs from Lancet Oncology
#54
of 6,943 outputs
Outputs of similar age
#1,082
of 350,554 outputs
Outputs of similar age from Lancet Oncology
#2
of 132 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,943 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.3. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 350,554 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 132 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.